WHITE PAPER

Hydroxyl Radical Protein Footprinting: A Breakthrough Technique for Epitope Mapping


Epitope mapping is critical in therapeutic antibody development. 

But common epitope mapping techniques, like x-ray crystallography, peptide scanning, mutagenesis, and hydrogen-deuterium exchange (HDX), all have significant limitations and drawbacks that end up costing drug developers significant time and expense.

Epitope mapping by hydroxyl radical protein footprinting (HRPF) is a technique that circumvents some of the major drawbacks of currently used methods for analyzing antibody-antigen interactions—thereby accelerating drug discovery.

In this paper, we provide a clear and concise introduction to epitope mapping, explore its essential role in drug development, and explain, with evidence, how epitope mapping by HRPF analyzes proteins in a fraction of the time and at a fraction of the cost and complexity compared to traditional techniques.

ABOUT THE GUIDE

Here’s the main idea.

Therapeutic antibodies constitute one of the fastest areas of growth in the field of biologic drugs. Mapping the binding sites (or epitopes) of antibodies and their target antigens is critical for understanding their mechanism of action as well as filing patent claims. 

The techniques that are commonly used for epitope mapping, including x-ray crystallography, peptide scanning, mutagenesis, and hydrogen-deuterium exchange (HDX), all have significant limitations and drawbacks. 

An orthogonal technique for protein footprinting is called hydroxyl radical protein footprinting, which uses hydroxyl radicals to detect changes in solvent accessibility of protein side chains. Epitope mapping by HRPF is attracting the attention of top pharmaceutical companies and biotechnology firms looking to condense the discovery process and curtail the millions of dollars often poured into protein analysis by providing an accurate snapshot of a protein in a fraction of the time.

This paper gives you the information and evidence you need to understand how it works, where it can be applied, and whether it may give your organization an advantage in streamlining drug discovery and development.

Submit the form below and we'll send the white paper right to your inbox.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
THE INSIDE LOOK

Everything you need to know about modern epitope mapping techniques—and how to apply them.

This paper covers the basics of epitope mapping, summarizes the latest published research into its functions and utility, and provides a highly practical look at how modern techniques are poised to give biologic companies a significant competitive advantage at a traditional slow phase of the development lifecycle.

It's essential reading for anyone involved in drug R&D looking to stay informed of new technologies and techniques for streamlining discovery and development.

You’ll get: 

A concise introduction to modern epitope mapping

A look at the current techniques used to perform epitope mapping

Actionable summaries of protein footprinting for epitope mapping

A case study demonstrating a cutting-edge technique in practice

THE BENEFITS

See how your development lifecycle stands to gain from the latest techniques in epitope mapping.

Get a practical, applied look at epitope mapping in biologic drug development.

See why epitope mapping is important for antibody discovery.

Explore the current techniques: Hydrogen Deuterium eXchange and Hydroxyl Radical Protein Footprinting

See the benefits of using PLIMB for HRF.

YOU'RE IN GOOD COMPANY

See the technology used by other innovators to streamline biologic development.

We’ve attracted the attention of industry leaders, investors, and clients, including the top pharmaceutical companies and biotechnology firms in the US, and these esteemed institutional partners.

"Unlike other techniques, hydroxyl radical footprinting allows you to see how a protein is moving around in solution. And it’s much faster. It’s extremely useful to any company that wants to engineer the next billion-dollar drug."

— MiCHaEL Sussman, PhD, CO-FOUNdER & CSO, IMMUTO SCIENTIFIC